Barclays PLC Has $35.86 Million Stake in Catalent, Inc. (NYSE:CTLT)

Barclays PLC decreased its position in Catalent, Inc. (NYSE:CTLT) by 1.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 269,477 shares of the company’s stock after selling 4,735 shares during the period. Barclays PLC’s holdings in Catalent were worth $35,858,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Integrated Investment Consultants LLC boosted its stake in shares of Catalent by 1.1% during the 3rd quarter. Integrated Investment Consultants LLC now owns 7,683 shares of the company’s stock valued at $1,022,000 after buying an additional 80 shares during the period. Advisor Partners LLC boosted its stake in shares of Catalent by 3.8% during the 2nd quarter. Advisor Partners LLC now owns 2,545 shares of the company’s stock valued at $275,000 after buying an additional 92 shares during the period. Old North State Trust LLC boosted its stake in shares of Catalent by 8.3% during the 3rd quarter. Old North State Trust LLC now owns 1,218 shares of the company’s stock valued at $162,000 after buying an additional 93 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Catalent by 33.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 402 shares of the company’s stock valued at $44,000 after buying an additional 101 shares during the period. Finally, IFM Investors Pty Ltd boosted its stake in shares of Catalent by 0.5% during the 3rd quarter. IFM Investors Pty Ltd now owns 22,357 shares of the company’s stock valued at $2,975,000 after buying an additional 106 shares during the period. 97.12% of the stock is owned by hedge funds and other institutional investors.

Shares of CTLT opened at $108.24 on Friday. The company has a market capitalization of $18.53 billion, a PE ratio of 34.15, a price-to-earnings-growth ratio of 1.86 and a beta of 1.32. Catalent, Inc. has a one year low of $97.86 and a one year high of $142.64. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.59 and a quick ratio of 3.02. The company’s fifty day moving average price is $124.44 and its 200 day moving average price is $125.70.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, November 1st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.06. Catalent had a net margin of 13.68% and a return on equity of 14.64%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm posted $0.33 EPS. Analysts anticipate that Catalent, Inc. will post 3.51 earnings per share for the current year.

In other news, insider Karen Flynn sold 2,472 shares of Catalent stock in a transaction dated Monday, January 10th. The shares were sold at an average price of $116.64, for a total transaction of $288,334.08. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gregory T. Lucier sold 5,068 shares of Catalent stock in a transaction dated Tuesday, November 23rd. The shares were sold at an average price of $127.35, for a total transaction of $645,409.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,009,847 shares of company stock worth $389,142,882. Insiders own 0.53% of the company’s stock.

A number of research firms have recently weighed in on CTLT. Royal Bank of Canada raised their price target on shares of Catalent from $145.00 to $155.00 and gave the company an “outperform” rating in a report on Wednesday, November 3rd. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $143.00 price target on the stock in a report on Tuesday, January 4th. Barclays began coverage on shares of Catalent in a report on Thursday, December 16th. They set an “overweight” rating and a $160.00 price target on the stock. Finally, Morgan Stanley raised their price target on shares of Catalent from $147.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, November 3rd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $153.33.

Catalent Profile

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Featured Story: Strangles

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.